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ABSTRACT: 27 
The aim of this work is to characterize possible modifying factors in two large families 28 
carrying the A1555G mitochondrial mutation. The heteroplasmy of the mutation, the 29 
presence of aminoglysosides, the co-segregation with other mitochondrial mutations, the 30 
proposed linkage in chromosome 8 and the association with TRMU and MTO1 genes were 31 
studied. None of the mentioned modifying factors were related with the phenotype 32 
presentation of A1555G mutation. However TRMU G28T SNP is present in one of the 33 
studied families. 34 
 3 
INTRODUCTION 35 
Neurosensory, maternally inherited, non-syndromic deafness is a disease that may be 36 
provoked by specific mutations in mitochondrial DNA (mtDNA). The most common of 37 
these mutations is the A1555G substitution that arises in the gene encoding the 12S 38 
mitochondrial ribosome subunit [Prezant et al. 1993]. Although this mutation is considered 39 
as the primary cause of neurosensory deafness, biochemical [Guan et al. 2001;Guan et al. 40 
2000] and clinical [el Schahawi et al. 1997] evidence suggests that other environmental or 41 
nuclear factors might modulate the phenotype of these disorders. Such modulating factors 42 
include: 43 
Exposure to aminoglycosides. The A1555G mutation was initially described in subjects 44 
with both antibiotic-induced and non-syndromic deafness [Prezant et al. 1993]. 45 
Moreover, various patients were later identified that carried this mutation and that 46 
developed deafness without having been exposed to aminoglycosides [Li et al. 2004;el 47 
Schahawi, Lopez, Sarrazin, Shanske, Basirico, Shanske, and DiMauro1997]. Thus, it 48 
appears that exposure to these compounds is not required for the appearance of this 49 
phenotype [Estivill et al. 1998].  50 
Heteroplasmy of the mutation. In the vast majority of studies on A1555G, this mutation 51 
was described as homoplasmic but some studies have presented families with different 52 
levels of heteroplasmy. These studies have proposed that the level of heteroplasmy could 53 
influence the clinical manifestations of the disease [el Schahawi, Lopez, Sarrazin, 54 
Shanske, Basirico, Shanske, and DiMauro1997;del Castillo et al. 2003].  55 
Co-segregation with other mtDNA mutations. Polymorphisms in mtDNA could 56 
influence the penetrance of pathogenic mutations responsible for other mitochondrial 57 
disorders. For example, it is thought that primary pathogenic mutations exist in Lebers’ 58 
disease and that secondary mutations, which are not intrinsically pathogenic, influence 59 
the expression of the primary mutations [Torroni et al. 1997]. It was proposed that 60 
 4 
various alterations in the mtDNA sequence may modulate the phenotypic expression of 61 
the A1555G mutation [Li, Xing, Yan, Cao, Liu, Bu, and Guan2004;Pandya et al. 62 
1999;Finnila et al. 2001]. Other alterations in the mitochondrial genome that cause 63 
neurosensory non-syndromic deafness and that could co-segregate with A1555G are the 64 
changes A7445G, 7472 insC, T7510C, T7511C [Fischel-Ghodsian 1999] or C1494T 65 
[Zhao et al. 2004].  66 
Nuclear genes may also be candidates to functionally interact with and modify the 67 
mutated 12S rRNA, influencing the phenotypic expression of the A1555G mutation. 68 
Genome linkage studies propose that a locus in chromosome 8 might be linked to the 69 
disease [Bykhovskaya et al. 1998;Bykhovskaya et al. 2000], but this linkage has not 70 
been replicated and no mutations have been found in the proposed modifying genes. 71 
Studies in the yeast Saccharomyces cerevisae have proposed the MTO1, MSS1 and 72 
MTO2 genes as strong candidates to modulate the effect of the mutation. Accordingly, 73 
MTO2 can complement the respiratory-deficient phenotype of yeast cells carrying the 74 
C1409G mutation in the 15S rRNA. Indeed, a G28T missense mutation in the TRMU 75 
gene (a homologue of MTO2) was identified in 613 subjects with non-syndromic 76 
deafness from families of different ethnic origins, altering a conserved amino acid 77 
(Alanine). Functionally, this mutation does not affect the import of TRMU precursors but 78 
it does lead to a marked failure in mitochondrial tRNA metabolism [Guan et al. 2006]. 79 
These findings support the role of TRMU as a modulating factor of deafness-associated 80 
A1555G mutation. 81 
 82 
In the current study, we analyzed possible modifying factors in two families carrying the 83 
A1555G mutation in which deafness was observed, in order to explain the differences in the 84 
phenotype between the carriers of the mutation. In these families, the heteroplasmy of the 85 
mutations was studied, as well as their co-segregation with other mitochondrial mutations in 86 
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the 12S gene, and the proposed linkage with a region in chromosome 8, and with the TRMU 87 
and MTO1 sequences. 88 
METHODS 89 
The two families examined in this study were of Spanish origin and they have been partially 90 
described in another study [el Schahawi, Lopez, Sarrazin, Shanske, Basirico, Shanske, and 91 
DiMauro1997]. All the individuals studied were interviewed at the Neurology Service of the 92 
Hospital Donostia. Of 38 individuals in these families (18 male, 20 female), 19 (9 males, 10 93 
females) were diagnosed with neurosensory non-syndromic deafness. 94 
Molecular studies 95 
After obtaining the informed consent of each subject, DNA was extracted from peripheral 96 
blood by standard methods [Miller et al. 1988]. The control samples were taken from a DNA 97 
bank maintained by the Neurology Service of the Hospital Donostia and these controls were 98 
from individuals that did not suffer any neurological complaint. 99 
Study of the A1555G mutation  100 
The presence of the A1555G mutation was determined by PCR-RFLP [el Schahawi, Lopez, 101 
Sarrazin, Shanske, Basirico, Shanske, and DiMauro1997]. A 94 bp fragment was amplified 102 
(see primers in Table I) using a reverse mismatch primer that generated a novel restriction 103 
site in conjunction with the mutation. The presence or absence of the mutation could 104 
therefore be determined by complete digestion of the PCR product O/N with the restriction 105 
enzyme Hae III (New England Biolabs), and by analyzing the digestion products by 106 
electrophoresis in a 4 % agarose gel. The novel restriction site generated by the presence of 107 
the mutated allele (1555G) gives rise to two bands of 64 and 30 bp upon digestion, while the 108 
normal allele (1555A) is not digested by the enzyme and thus, a 94 bp band is detected. In 109 
this way the carriers of the mutation can be easily differentiated. 110 
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Quantification of the heteroplasmy level 111 
The level of heteroplasmy in mitochondrial mutations has classically been measured by 112 
densitometry of the bands obtained in 32P labeled RFLP studies. Since it is not currently 113 
clear which is the best technique to measure heteroplasmy [Jacobi et al. 2001;Ren-Kui B and 114 
Lee-Jun C.Wong 2004], we have used two methods to measure this phenomenon: 115 
- The first method involved capillary electrophoresis of the PCR-RFLP products in an 116 
ABIPRISM 310 analyzer. As noted above, the reverse mismatch primer creates a new 117 
Hae III target when the DNA carries the mutation while the forward primer was labeled 118 
with TAMRA. Two different peaks were detected after O/N enzyme digestion, the wild-119 
type peak (94 pb) and the mutated peak (64 pb). In the heteroplasmic subjects, the 120 
proportion of the mutated molecules was estimated by the relation between the peak´s 121 
areas using the GENESCAN and GENOTYPER softwares (Applied Biosystems). Each 122 
digestion product was run twice and each digestion was performed three times from three 123 
independent PCR reactions. The percentage heteroplasmy was calculated as the mean of 124 
the six results. 125 
- The other method relied on qPCR SNP detection technology, using a 7300 qPCR genetic 126 
analyzer (Applied Biosystems) and a SNP assay with probes specifically designed by 127 
Applied Biosystem to detect the A1555G SNP. To establish the level of heteroplasmy, 128 
the Ct of each probe (normal and mutated) was compared [Bai and Wong 2004] using 129 
SDS v1.3.1 software from Applied Biosystems. We checked each probe in 45 healthy 130 
controls to be sure that the mutated probe was sufficiently specific. Each assay was 131 
repeated three times and the value presented corresponds to the mean of these three 132 
measurements.  133 
 134 
Study of the mitochondrial variations 135 
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By sequencing a 1141 bp amplicon of mtDNA that includes the MTRNR1 gene (see primers 136 
in Table I) we studied an affected individual and a carrier of the mutation in each family 137 
(individual III-11 of family 1 and IV-3 of family 2), as well as three control individuals. 138 
Likewise, the mitochondrial mutations: 961 insC, G7444A, A7445G, 7472 insC, T7510C, 139 
T7511C and C1494T were studied in all the family members (affected and unaffected). The 140 
A4336G alteration was analyzed by PCR-RFLP with the enzyme Nla III (New England 141 
Biolabs) rather than by sequencing. The 4336A allele generates a 313 bp fragment while the 142 
allele 4336G generates two fragments of 244 bp and 69 bp that can being differentiated by 143 
electrophoresis in a 2 % agarose gel.. Each sample was ascribed to one of the following 144 
haplogroups, H, U, JT or Y, according to previously published protocols [Otaegui et al. 145 
2004]. 146 
All the mitochondrial primers (sequences available on request) were designed using the 147 
mitochondrial sequence AC_001807.  148 
Linkage studies 149 
The linkage study was performed using the following markers: D8S277, D8S561, D8S1819 150 
and D8S1825 with HEX labeled primers and under the amplification conditions described in 151 
the GDB database [2004a]. The PCR products were run in an ABIPRISM 310 genetic 152 
analyzer and analyzed with the GENESCAN software. The lod score was calculated using 153 
the LCP software package. 154 
Candidate nuclear gene sequencing 155 
The MTO1 gene was studied by direct sequencing of the coding exons in: one patient (IV-156 
28) from family 1, one asymptomatic individual that is a carrier of the A1555G mutation 157 
(III-5) from family 1, one patient from family 2 (III-5) and one healthy control unrelated 158 
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with either family. The MTO1 primers (available on request) were designed using the 159 
sequence ENST00000323606. 160 
 161 
The coding exons of the TRMU gene were also studied by direct sequencing in the following 162 
individuals: III-10, III-14, IV-40, V-2 and V-6 from family 1; III-9, IV-3 and IV-4 from 163 
family 2. The primers (available on request) were designed from the NC_000022.9 164 
sequence. The presence of the G28T mutation was ascertained by PCR-RFLP using 165 
previously reported methods [Guan, Yan, Li, Bykhovskaya, Gallo-Teran, Hajek, Umeda, 166 
Zhao, Garrido, Mengesha, Suzuki, Del Castillo, Peters, Li, Qian, Wang, Ballana, Shohat, Lu, 167 
Estivill, Watanabe, and Fischel-Ghodsian2006]. We examined this mutation in 256 healthy 168 
subjects. 169 
All sequencing reactions were carried out in a 310 or a 3130 Applied Biosystem genetic 170 
analyzer following the manufacturer’s recommendations. 171 
RESULTS 172 
Heteroplasmy levels 173 
The data from the distinct analyses of heteroplasmy by Genescan qPCR and by 174 
electrophoresis were compared (Table 1). The genescan technique detects levels of 175 
heteroplasmy between 0.8% and 98 % in both families, finding more heteroplasmy in the 176 
family 2. The study in controls with qPCR shows that the mutated probe was highly specific, 177 
giving an error of less than 1% (data not shown), this technique detects heteroplasmy only in 178 
family 2 (patients II-2 and III-1) 179 
 180 
Mitochondrial SNPS 181 
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None of the following mitochondrial mutations were found in any of the individuals studied: 182 
961 insC, A4336G, A7445G, 7472 insC, T7510C, or the T7511C. Family 1 can be 183 
considered within the haplogroup JT, and family 2 in the haplogroup H. 184 
We characterized several homoplasmic changes in the 12S mitochondrial gene sequence. At 185 
nucleotide 750, we identified the AG transition in all the samples analyzed (patients and 186 
controls). In contrast, a transversion (CG) was detected at position 1438 in the two 187 
families studied and it was not evident in the controls, thereby segregating with the A1555G 188 
mutation. Furthermore, a TC transition was observed at position 1193 in family 2 but not 189 
in the other family.  190 
Linkage and nuclear genes 191 
The linkage analysis generated lod scores between -0.5 and -2.5, ruling out the possible 192 
linkage of the chromosome 8 region with the disease (data available on request). 193 
 194 
The sequence of MTO1 coding exons in the families studied did not show any difference in 195 
the families when compared with the controls. 196 
 197 
Likewise, no mutations were detected in the TRMU sequences except for the previously 198 
reported G28T mutations (see Fig 2). This mutation was only present in family 1, where it 199 
was detected in 14 heterozygous individuals, six of whom were deaf and 8 healthy, and in 200 
one homozygous-deaf subject. When 256 control subjects were analyzed, the proportion of 201 
heterozygotes was 12.1 % and only 1 homozygous subject was identified (0.004%). 202 
 203 
DISCUSSION  204 
In two Spanish families suffering from maternally inherited neurosensory non-syndromic 205 
deafness, we have analyzed different molecular changes that have been proposed as possible 206 
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modifying factors associated with the A1555G mutation [el Schahawi, Lopez, Sarrazin, 207 
Shanske, Basirico, Shanske, and DiMauro1997]. Accordingly, we analyzed the degree of 208 
heteroplasmy, the presence of mitochondrial mutations, the proposed linkage to chromosome 209 
8 and the role of the MTO1 and TRMU genes in these families and in healthy controls. 210 
 211 
Heteroplasmy  212 
Although the A1555G mutation is usually described as displaying a homoplasmic 213 
inheritance, individuals with heteroplasmic mutations have been described [del Castillo, 214 
Rodriguez-Ballesteros, Martin, Arellano, Gallo-Teran, Morales-Angulo, Ramirez-Camacho, 215 
Cruz, Solanellas, Martinez-Conde, Villamar, Moreno-Pelayo, Moreno, and del, I2003;el 216 
Schahawi, Lopez, Sarrazin, Shanske, Basirico, Shanske, and DiMauro1997]. Indeed, it was 217 
established that the mutated copies ranged between 3.75 and 96.60 % in these heteroplasmic 218 
individuals and a pathogenic threshold was proposed between 20 and 52 % . According to 219 
these conclusions, individuals with less than 20 % of mutated copies would be asymptomatic 220 
while the individuals with more than 52 % would be deaf. However, these affirmations do 221 
not correlate with the existence of healthy homoplasmic carriers of the mutation, as occurs 222 
both in our families and in families reported elsewhere.  223 
 224 
Instead of the classical densitometry methods, we have used two different techniques to 225 
measure the degree of heteroplasmy that avoid the use of radioactivity. A technical 226 
comparison of these two methods showed slight differences between the percentages 227 
obtained by genescan or by qPCR. In the genescan approach, we use a restriction enzyme 228 
and a mismatch primer and these two conditions increase the variability of the technique, 229 
particularly in the values close to the extremes (0 and 100). Such problems were not 230 
associated with the use of qPCR, which displays less variability between replicates than 231 
genescan. However, based on the control results qPCR may have an error of 1% in terms of 232 
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the estimation of the percentage level of mutation. Nevertheless, we believe that these two 233 
approaches are more realistic and more efficient than the densitometry approach. 234 
 235 
In family 1 the mutation always appears as homoplasmic and while the pattern is clearly 236 
maternal, we found several carrier individuals without symptoms (III-10, III-21, III-15, IV-9, 237 
V-1 y V-8 in Fig 2A). Such asymptomatic carriers have also been found in other families, 238 
sustaining the existence of modulating factors. In contrast, heteroplasmic individuals were 239 
identified in family 2, the degree of heteroplasmy ranging between 71.186 (II-2) and 93.214 240 
% (III-1). Similarly, asymptomatic homoplasmic carriers were identified (IV-4) which 241 
makes it impossible to establish a pathogenic threshold. The III-9 individual in this family 242 
should be a carrier of the mutation but does not present the A1555G mutation. The genotype 243 
of this individual could be explained by non-equitable mitochondrial segregation during 244 
oogenesis in the mother which produces two or more ovule types with high levels of the 245 
mutation or with no mutated copies. This phenomenon, named “bottle neck” could be 246 
defined as the minimal number of mitochondrial genetic copies which occurs during oocyte 247 
formation and early development which maximizes genetic drift for a heteroplasmic mother.  248 
It has been described in other mitochondrial diseases, and non-equitable A1555G inheritance 249 
in the offspring of the carrier mothers was described by Del Castillo et al, supporting the 250 
possible occurrence of such a bottle neck. Moreover, we must take into account that our 251 
study was carried out on blood and thus, the values obtained might not be representative of 252 
the affected tissue. Although several authors have tried to explain the mechanisms behind 253 
heteroplasmic inheritance, they still remain unclear [Battersby B et al. 2003;Jenuth JP et al. 254 
1996].  255 
In conclusion, the two families studied here carry a homoplasmic A1555G mutation on the 256 
one hand and in the other, the A1555G mutation is clearly heteroplasmic. In both families 257 
homoplasmic carriers were identified that did not display any symptoms. 258 
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Mitochondrial mutations 259 
The MTRNR1 gene, in which the A1555G mutation is located, encodes the ribosomal 12S 260 
subunit. Hence, any other alteration in the sequence of this gene could affect the spatial 261 
conformation of this subunit and act in conjunction with the A1555G mutation to modulate 262 
its effects. Several different polymorphisms in this gene have been proposed as factors that 263 
might modulate this disease (see introduction) and our data clearly indicate that the transition 264 
at nucleotide 750 can be considered as a polymorphism. This alteration appears with a 265 
similar frequency in both the healthy group of subjects and in the patients, and as such it is 266 
most likely to be a polymorphism rather than being related with the disease.  267 
The C1438G transversion was also present in both families but it was not identified in the 268 
control subjects. Moreover, this alteration has been described as a polymorphism in the 269 
MITOMAP database [2004b]. This transversion was also identified in another study on the 270 
relationship between mitochondria and deafness both in, patients and control subjects 271 
[Yamasoba et al. 2002]. Accordingly, its potential implication in this disease remains 272 
unclear. Indeed, this substitution could be a population polymorphism that is found at greater 273 
frequency in carriers of the A1555G mutation. In order to evaluate this possibility, it will be 274 
necessary to determine the presence of this polymorphism in a larger number of A1555G 275 
carriers. 276 
The nucleotide change 1193(TC) appears exclusively in family 2 and it is not included in 277 
the databases. It occurs at a nucleotide that is not highly conserved across evolution, and that 278 
is found between structural helix 32 and 33 of the 12S subunit [Hickson R et al. 1996]. This 279 
could be a rare polymorphism or alternatively, a cofactor that modulates the effects of the 280 
A1555G mutation in an analogous manner to that seen for the secondary mutations in 281 
LEBER disease. However, the fact that the polymorphism segregates with the mutation does 282 
not explain the existence of asymptomatic carriers. 283 
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 284 
In summary, all the mitochondrial changes encountered appear to be polymorphisms that are 285 
not related with the incomplete penetrance of the A1555G mutation. However, it will be 286 
important to carry out an analysis in larger series of patients to study the effects of these 287 
changes on the expression of the A1555G mutation. 288 
Linkage mutations and candidate genes  289 
The proposed positive linkage of the 8q23 region [Bykhovskaya et al. 2001] has not been 290 
verified either by our data or in an earlier study [Finnila and Majamaa 2003], so the linkage 291 
of this region with the disease remains unclear. 292 
The MTO1 gene, located in chromosome 6 has been proposed as a candidate gene to 293 
modulate the effects of the A1555G mutation. When mutated it produces a deficit in the 294 
production of the respiratory channel, but only when the mtDNA of this cells carries the 295 
PR454 mutation, equivalent to the human A1555G mtDNA mutation [Colby et al. 1998]. Like 296 
two other studies [Finnila and Majamaa2003;Bykhovskaya et al. 2004], we found no 297 
mutations in this gene in our families, and this gene could thus be discarded as an factor 298 
influencing this disease. 299 
In 2006, it was proposed that the G28T mutation in the TRMU gene was associated with this 300 
disease [Guan, Yan, Li, Bykhovskaya, Gallo-Teran, Hajek, Umeda, Zhao, Garrido, 301 
Mengesha, Suzuki, Del Castillo, Peters, Li, Qian, Wang, Ballana, Shohat, Lu, Estivill, 302 
Watanabe, and Fischel-Ghodsian2006]. This variant was found in around a 25% of two 303 
cohorts carrying the A1555G mutation (one Arab-Israeli and one European), while it was 304 
only present in 10% of Jewish and white controls. The mutation is not present in either 305 
controls or families suffering deafness in the Chinese population. Biochemically, the G28T 306 
mutation was shown to aggravate the mitochondrial dysfunction caused by the A1555G 307 
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mutation [Guan, Yan, Li, Bykhovskaya, Gallo-Teran, Hajek, Umeda, Zhao, Garrido, 308 
Mengesha, Suzuki, Del Castillo, Peters, Li, Qian, Wang, Ballana, Shohat, Lu, Estivill, 309 
Watanabe, and Fischel-Ghodsian2006]. According to this hypothesis, the G28T mutation 310 
acts in synergy with the mitochondrial mutation, lowering the mitochondrial translation 311 
process below the pathogenic threshold and thereby causing the phenotype.  312 
In our cohorts, both of Spanish origin, we found the G28T mutation in 15 out of 28 members 313 
in family 1. The mutation appears more frequently in this family than in normal controls, 314 
consistent with the proposed modifying role. However, in this family we did not find a 315 
correlation between the genotype and phenotype, since we found heterozygous individuals 316 
carrying the mutation with and without deafness. In some families, including one presented 317 
here, this mutation seems to be a marker for the pedigree, but it not seems to be a modifying 318 
factor. More genes related to the complex set of factors involved in the mitochondrial 319 
translation process should be studied in relation with this phenomenon. 320 
In our families the A1555G mitochondrial mutation seems to be necessary but not sufficient 321 
to cause clinical symptoms. It therefore seems necessary to identify more susceptibility 322 
factors, probably SNPS in nuclear genes related with mitochondrial metabolism, to explain 323 
the inheritance of this disease. 324 
 325 
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Table 1 335 
 
FAMILY sample GeneS qPCR Gel 
Clinical 
Symptoms 
III-8 98.00 100.00% + YES 
III-10 96.00 100.00% + NO 
III-11 91.29 100.00% + NO 
III-12 1.00 0.10% - NO 
III-15 95.00 100.00% + NO 
IV-1 95.70 100.00% + YES 
IV-2 95.36 100.00% + YES 
IV-3 0.00 0.00% - NO 
IV-4 92.78 100.00% + YES 
IV-5 96.70 100.00% + YES 
IV-6 96.67 100.00% + YES 
IV-8 96.56 100.00% + YES 
IV-11 95.91 100.00% + YES 
IV-12 1.40 0.05% - NO 
IV-13 96.14 100.00% + NO 
IV-14 1.44  - NO 
IV-15 95.14 100.00% + YES 
IV-18 93.67 100.00% + YES 
IV-20 94.89 100.00% + YES 
IV-21 2.29 0.00% - NO 
IV-24 3.00 0.06% - NO 
V-1 96.00 100.00% + NO 
V-2 96.43 100.00% + YES 
V-3 94.78 100.00% + NO 
V-4 6.20 0.00% - NO 
V-5 1.25 0.07% - NO 
V-6 1.00 0.03% - NO 
V-7 2.29 0.04% - NO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAMILY 
1 
V-8 6.14 0.13% - NO 
II-2  81.67 71.19% ± NO 
III-1  67.71 93.22% ± YES 
III-5  78.50 99.97% + YES 
III-7  91.25 N.A + YES 
III-8  0.88 0.26% - NO 
IV-3  N.A 100.00% + YES 
IV-4  N.A 100.00% + ¿? 
IV-5  N.A 100.00% + YES 
 
 
 
 
 
 
FAMILY 
2 
IV-6_ 95.43 100.00% + YES 
Heteroplasmy observed using two techniques: GeneScan (GeneS) and quantitative PCR 336 
(qPCR), and compared with the electrophoresis results and the status of the individuals. The 337 
results of the RFLP in agarose gels are represented, whereby: + indicates the presence of 338 
the mutation; a negative result is represented by -; and both symbols indicate that the RFLP 339 
indicates the existence of hetroplasmy. ND: Not available. 340 
 341 
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Table 2. 342 
Change Nucleotide Fam 1, III-11 Fam 2, IV-3 Controls MITOMAP 
AG 750 YES YES YES Polymorphism 
C G 1438 YES YES NO DM associated 
polymorphism 
TC 1193 NO YES NO  
 343 
Changes in the 12S mitochondrial gene. DM: Diabetes Mellitus 344 
 345 
 346 
 347 
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 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
Family 1. Deaf individuals are indicated by black symbols 358 
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-
-
- -
-
- - - -
- -
B
A
359 
+: A1555G  carrier, - : No A1555G carrier, _/_: TRMU ntd 28 genotype. A: Family 1 abbreviated. B: Family 2 showing the percentage of heteroplasmy, all 
the members are carriers of the G/G genotype at ntd 28. Deaf individuals are indicated by black symbols 
 20 
 21 
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